In the Clinic: Triple Combination CFTR Modulation
Elexacaftor/tezacaftor/ivacaftor — the newly approved triple combination CFTR modulator therapy. What are the benefits? For which patients? What are the potential adverse effects? Who’s most likely to receive them? In this issue, Dr. Scott Sagel from the Breathing Institute at the Children’s Hospital Colorado, part of the University of Colorado’s Anschutz Medical Campus, takes us to the clinic to discuss some answers. Take our post-test to claim CME credits. To read a companion newsletter click here.
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of eCysticFibrosis Review?
This episode is 25 minutes long.
When was this eCysticFibrosis Review episode published?
This episode was published on June 2, 2020.
Can I download this eCysticFibrosis Review episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.